Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel adjuvant systems.

M J McCluskie1, R D Weeratna

  • 1Coley Pharmaceutical Canada, 725 Parkdale Avenue, Ottawa, K1Y 4E9, Canada. mmccluskie@coleypharma.com

Current Drug Targets. Infectious Disorders
|November 29, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a recombinant murine tumour model using hepatoma cells expressing hepatitis C virus nonstructural antigens.

Journal of viral hepatitis·2018
Same author

Mucosal immunization with DNA vaccines.

Methods in molecular medicine·2011
Same author

Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.

Current topics in microbiology and immunology·2006
Same author

Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters.

Gene therapy·2002
Same author

CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.

FEMS immunology and medical microbiology·2001
Same author

The potential of CpG oligodeoxynucleotides as mucosal adjuvants.

Critical reviews in immunology·2001

Novel vaccine adjuvants, including bacterial toxins and immunomodulators, are crucial for enhancing vaccine performance and developing new vaccines. This review explores recent advancements in these promising adjuvant systems.

Area of Science:

  • Immunology
  • Vaccinology
  • Biotechnology

Background:

  • Vaccination is a cornerstone of infectious disease prevention.
  • There is a continuous need for improved vaccine efficacy, requiring fewer doses or novel approaches.
  • Development of safe and effective adjuvants is critical for human vaccines.

Purpose of the Study:

  • To review recent findings on novel adjuvant systems for vaccine development.
  • To highlight the potential of various adjuvant classes in enhancing immune responses.

Main Methods:

  • Literature review of recent advancements in adjuvant research.
  • Categorization and discussion of different novel adjuvant types.

Main Results:

Related Experiment Videos

  • Several classes of novel adjuvants have emerged, including bacterial toxins (CT, LT), immunomodulators (IL-2, IL-12, GM-CSF), saponins (QS-21), CpG ODN, lipid A derivatives (MPL), and MDP derivatives.
  • These adjuvants offer diverse mechanisms to enhance vaccine immunogenicity.

    • Conclusions:

    • Novel adjuvants represent a significant area of research for improving existing vaccines and creating new ones.
    • Continued investigation into these adjuvant systems is essential for advancing vaccine technology.